The Role of Antiplatelet and Antithrombotic Agents in Enhancing the Success of Interventional Cardiological Procedures

Naeem Khan; Farhat Ullah Khan; Muhammad Idrees Khan; Muzdalfa Parvez; Muhammad Musa

doi:10.70749/ijbr.v3i2.737

Authors

Naeem Khan Department of Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan.
Farhat Ullah Khan Department of Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan.
Muhammad Idrees Khan Department of Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan.
Muzdalfa Parvez Department of Cardiology, Hayatabad Medical Complex, Peshawar, Pakistan.
Muhammad Musa Department of Medicine and Allied, Khalifa Gul Nawaz Teaching Hospital MTI, Bannu, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i2.737

Keywords:

Antiplatelet, Antithrombotic, Interventional Cardiological Procedures, DAPT, Thrombotic Complications

Abstract

Objective: To investigate the role of antiplatelet and antithrombotic agents in enhancing the success of interventional cardiological procedures, focusing on their impact in reducing thrombotic complications and managing bleeding risks. Methodology: A retrospective study was conducted from January 2023 to December 2023 at Hayatabad Medical Complex, Peshawar. A total of 200 patients were included, with 100 patients in the DAPT group and 100 patients in the single-agent therapy group. Data were collected from patient records, assessing the intervention success, bleeding complications, thrombotic events, and cardiovascular outcomes. Statistical analysis included chi-square tests, independent t-tests, and Kaplan-Meier survival analysis with a significance level of p < 0.05. Results: The DAPT group demonstrated a significantly higher intervention success rate (90%) compared to the single-agent therapy group (80%) (p = 0.032). Bleeding complications were lower in the DAPT group (10%) versus the single-agent therapy group (20%) (p = 0.045). Thrombotic events occurred more frequently in the single-agent therapy group (15%) than the DAPT group (5%) (p = 0.012). No significant differences in cardiovascular events (MI and stroke) were observed between the groups (p = 0.078 and p = 0.180, respectively). Conclusion: DAPT is more effective in preventing thrombotic events and ensuring the success of interventional cardiological procedures, although it carries a higher bleeding risk. These findings support the use of DAPT in clinical practice, with careful management of bleeding risks.

Downloads

Download data is not yet available.

References

Siasos G, Tsigkou V, Bletsa E, Stampouloglou PK, Oikonomou E, Kalogeras K, et al. antithrombotic treatment in coronary artery disease. Curr Pharm Des 2023;29:2764–79. https://doi.org/10.2174/1381612829666230830105750.

Tscharre M, Michelson A, Gremmel T. novel antiplatelet agents in cardiovascular disease. J Cardiovasc Pharmacol Ther 2020;25:191–200. https://doi.org/10.1177/1074248419899314.

Galanti K, Di Marino M, Mansour D, Testa S, Rossi D, Scollo C, et al. current antithrombotic treatments for cardiovascular diseases: a comprehensive review. Rev Cardiovasc Med 2024;25. https://doi.org/10.31083/j.rcm2508281.

Roka-Moiia Y, Ammann K, Miller-Gutierrez S, Sheriff J, Bluestein D, Italiano J, et al. shear-mediated platelet microparticles demonstrate phenotypic heterogeneity as to morphology, receptor distribution, and hemostatic function. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms24087386.

Kyrle P, Eischer L, Šinkovec H, Gressenberger P, Gary T, Brodmann M, et al. the vienna prediction model for identifying patients at low risk of recurrent venous thromboembolism: a prospective cohort study. Eur Heart J 2023;45:45–53. https://doi.org/10.1093/eurheartj/ehad618.

Lordan R, Tsoupras A, Zabetakis I. platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: potential role of antiplatelet agents. Blood Rev 2020:100694. https://doi.org/10.1016/j.blre.2020.100694.

Golla K, Yasgar A, Manjuprasanna V, Naik M, Baljinnyam B, Zakharov A, et al. small-molecule disruptors of the interaction between calcium- and integrin-binding protein 1 and integrin αiibβ3 as novel antiplatelet agents. ACS Pharmacol Transl Sci 2024;7 7:1971–82. https://doi.org/10.1021/acsptsci.4c00026.

Wang T, Svensson L, Wen J, Vekstein A, Gerdisch M, Rao V, et al. apixaban or warfarin in patients with an on-x mechanical aortic valve. NEJM Evid 2023;2 7. https://doi.org/10.1056/evidoa2300067.

Arockiam S, Staniforth B, Kepreotis S, Maznyczka A, Bulluck H. a contemporary review of antiplatelet therapies in current clinical practice. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms241311132.

Davanzo RH, Alarcon AF, Calquin JQ, Varela P, Sepúlveda A, Herreros RC, et al. antiplatelet therapy and percutaneous coronary interventions. Curr Cardiol Rev 2020;17:232–43. https://doi.org/10.2174/1573403X16666200615144423.

Rapti E, Adamantidi T, Efthymiopoulos P, Kyzas G, Tsoupras A. potential applications of the anti-inflammatory, antithrombotic and antioxidant health-promoting properties of curcumin: a critical review. Nutraceuticals 2024. https://doi.org/10.3390/nutraceuticals4040031.

Averkov O V. early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk. Russ J Cardiol 2021;26:128–36. https://doi.org/10.15829/1560-4071-2021-4305.

Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R. evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J 2021;42:339–51. https://doi.org/10.1093/eurheartj/ehaa824.

Saigal K, Patel AB, Lucke-Wold B. artificial intelligence and neurosurgery: tracking antiplatelet response patterns for endovascular intervention. Medicina (B Aires) 2023;59. https://doi.org/10.3390/medicina59101714.

Lin S, Chang Y, Lin F, Tang S, Dong Y, Wang C. post‐intracranial hemorrhage antithrombotic therapy in patients with atrial fibrillation. J Am Heart Assoc 2022;11. https://doi.org/10.1161/JAHA.121.022849.